@theoc, yeah mate, very sketchy collaboration.....couple of...

@theoc, yeah mate, very sketchy collaboration.....couple of interesting points....
1....we retain Efti license.....very important for us good guys.
2...US trials mooted yet immutep hasn't been approved to conduct US trials as yet....
3....Does that mean trial conducted under Merck license?
4...Ridgeback and Lucy up the anti a bit, thus making it harder for a hostile takeover.
Nasdaq likely to take Holman's "renewed" interest favourably.
5....Merck interest will go very well in the biotech industry, expect some very positive
news items in the next few days...
6....You would have to think that Merck interest is because of Tacti-mel, a
Prima biomed/Immutep iniative where phase 1 results are imminent..In my
mind that means Tactimel will progress to ph2....

Take what I say with a grain of salt......